Foresite Capital Opportunity Fund V, L.p. - Net Worth and Insider Trading

Foresite Capital Opportunity Fund V, L.p. Net Worth

The estimated net worth of Foresite Capital Opportunity Fund V, L.p. is at least $19 Million dollars as of 2024-11-05. Foresite Capital Opportunity Fund V, L.p. is the 10% Owner of Pardes Biosciences Inc and owns about 8,773,134 shares of Pardes Biosciences Inc (PRDS) stock worth over $19 Million. Details can be seen in Foresite Capital Opportunity Fund V, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Foresite Capital Opportunity Fund V, L.p. has not made any transactions after 2023-04-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Foresite Capital Opportunity Fund V, L.p.

To

Foresite Capital Opportunity Fund V, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Foresite Capital Opportunity Fund V, L.p. owns 4 companies in total, including Kinnate Biopharma Inc (KNTE) , Disc Medicine Inc (IRON) , and Pardes Biosciences Inc (PRDS) among others .

Click here to see the complete history of Foresite Capital Opportunity Fund V, L.p.’s form 4 insider trades.

Insider Ownership Summary of Foresite Capital Opportunity Fund V, L.p.

Ticker Comapny Transaction Date Type of Owner
KNTE Kinnate Biopharma Inc 2020-12-02 10 percent owner
IRON Disc Medicine Inc 2020-10-19 10 percent owner
PRDS Pardes Biosciences Inc 2023-04-05 10 percent owner
LIMIT LIMIT 2022-06-09 10 percent owner

Foresite Capital Opportunity Fund V, L.p. Latest Holdings Summary

Foresite Capital Opportunity Fund V, L.p. currently owns a total of 1 stock. Foresite Capital Opportunity Fund V, L.p. owns 8,773,134 shares of Pardes Biosciences Inc (PRDS) as of April 5, 2023, with a value of $19 Million.

Latest Holdings of Foresite Capital Opportunity Fund V, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRDS Pardes Biosciences Inc 2023-04-05 8,773,134 2.16 18,949,969

Holding Weightings of Foresite Capital Opportunity Fund V, L.p.


Foresite Capital Opportunity Fund V, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Foresite Capital Opportunity Fund V, L.p. has made a total of 1 transactions in Pardes Biosciences Inc (PRDS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Pardes Biosciences Inc is the acquisition of 773,952 shares on April 5, 2023, which cost Foresite Capital Opportunity Fund V, L.p. around $1 Million.

Insider Trading History of Foresite Capital Opportunity Fund V, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Foresite Capital Opportunity Fund V, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Foresite Capital Opportunity Fund V, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Foresite Capital Opportunity Fund V, L.p. is 19.48%. GuruFocus also compares Foresite Capital Opportunity Fund V, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Foresite Capital Opportunity Fund V, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Foresite Capital Opportunity Fund V, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Foresite Capital Opportunity Fund V, L.p.

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 23.38 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 22.26 LIMIT LIMIT LIMIT LIMIT LIMIT

Foresite Capital Opportunity Fund V, L.p. Ownership Network

Ownership Network List of Foresite Capital Opportunity Fund V, L.p.

No Data

Ownership Network Relation of Foresite Capital Opportunity Fund V, L.p.

Insider Network Chart

Foresite Capital Opportunity Fund V, L.p. Owned Company Details

What does Kinnate Biopharma Inc do?

Who are the key executives at Kinnate Biopharma Inc?

Foresite Capital Opportunity Fund V, L.p. is the 10 percent owner of Kinnate Biopharma Inc. Other key executives at Kinnate Biopharma Inc include director & 10 percent owner James B. Tananbaum , 10 percent owner Foresite Capital Fund Iv, L.p. , and director & 10 percent owner Orbimed Capital Gp Viii Llc .

Kinnate Biopharma Inc (KNTE) Insider Trades Summary

Over the past 18 months, Foresite Capital Opportunity Fund V, L.p. made no insider transaction in Kinnate Biopharma Inc (KNTE). Other recent insider transactions involving Kinnate Biopharma Inc (KNTE) include a net purchase of 1,780,000 shares made by James B. Tananbaum , and a net purchase of 1,780,000 shares made by Foresite Capital Fund Iv, L.p. .

In summary, during the past 3 months, insiders sold 0 shares of Kinnate Biopharma Inc (KNTE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kinnate Biopharma Inc (KNTE) were sold and 3,560,000 shares were bought by its insiders, resulting in a net purchase of 3,560,000 shares.

Kinnate Biopharma Inc (KNTE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Kinnate Biopharma Inc Insider Transactions

No Available Data

Foresite Capital Opportunity Fund V, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Foresite Capital Opportunity Fund V, L.p.. You might contact Foresite Capital Opportunity Fund V, L.p. via mailing address: 600 Montgomery Street, Suite 4500, San Francisco Ca 94111.